|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUȚIONALE
- The Moldovan Medical Journal
- Curierul Medical 2009 - 2016
- Curierul Medical, 2014
- Curierul Medical, 2014, Vol. 57, Nr. 5
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/7442
Title: | Tratamentul personalizat în carcinomul mamar |
Other Titles: | Personalized therapy for breast cancer |
Authors: | Fulga, V. |
Keywords: | breast cancer;personalized therapy;molecular subtypes |
Issue Date: | 2014 |
Publisher: | The Scientific Medical Association of the Republic of Moldova |
Citation: | FULGA, V. Tratamentul personalizat în carcinomul mamar. In: Curierul Medical. 2014, vol. 57, no 5, pp. 73-76. ISSN 1875-0666. |
Abstract: | Background: Breast carcinoma represents the most common cancer worldwide and the second main cause of death among women. It’s a complex
disease characterized by many morphological, clinical and molecular features. Traditionally, this disease has been classified according to histopathologic
criteria, known as the tumor, node and metastasis staging system. Because the classic concept was focusing only on the tumor morphology, it could not
fully capture the diversity of the disease. Another classification system, based on hormone receptors and gene expression profiling of different breast
cancers types have been developed. This classification dictates the optimal therapeutic approach and it is based on immunohistochemical markers, such
as the estrogen receptor, the progesterone receptor, the human epidermal growth factor receptor 2, basal cytokeratin CK5 and proliferation marker Ki67.
New technologies, polymerase chain reaction, microarrays make possible identification of new biomarkers involved in breast cancer development, survival
and invasion, which can be gradually incorporated into clinical trials. The aim of this study is to highlight the progress achieved in the field of diagnosis
and management of breast cancer, using molecular analysis and intrinsic subtypes, commonly accepted in oncology practice.
Conclusions: Mammary carcinoma represents heterogenous pathologic entity that is characterised by genetic abnormalities and specific intra/
extracelullar pathways, grouped in intrinsic molecular subtypes identifiable with the help of immunohistochemistry. Modern therapy is based on
molecular subtypes; meanwhile their descrimination represents the initial step of personalised treatment. |
metadata.dc.relation.ispartof: | Curierul Medical |
URI: | http://repository.usmf.md/handle/20.500.12710/7442 http://moldmedjournal.md/wp-content/uploads/2016/09/Cm-5-Electronic-version-2.pdf |
ISSN: | 1875-0666 |
Appears in Collections: | Curierul Medical, 2014, Vol. 57, Nr. 5
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|